Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S448 Introduction: We report results from TRANSCEND FL (NCT04245839) in patients with R/R FL, with safety in all lisocel–treated patients (ie, second-line or later [2L+]; safety set) and efficacy focused on third-line or later (3L+) patients. Methods: Eligible patients with R/R FL included 3L+ patients and second-line patients with progression within 24 months of diagnosis (POD24) and/or modified Groupe d’Etude des Lymphomes Folliculaires (GELF) criteria. All patients received ≥1 prior combination systemic therapy, including an anti-CD20 antibody plus alkylator. Patients received liso-cel after lymphodepleting chemotherapy. Bridging therapy was allowed. Primary endpoint was ORR, per independent review committee (IRC), by PET/CT using Lugano 2014 criteria. Secondary endpoints included CR rate, duration of response (DOR), PFS, OS, safety, and PK. Results: At data cutoff (01/27/2023), of 139 leukapheresed patients, 130 (94%) received liso-cel and 124 (89%) were efficacy evaluable (EE) per IRC. In 3L+ FL patients, 43% had POD24, 53% met GELF criteria, and 64% were double refractory to anti-CD20 antibody plus alkylator. Median (range) prior lines of therapy was 3 (2-10). Median (range) follow-up was 18.9 months (0.3-28.2). In 3L+ EE patients (n=101), the primary endpoint of ORR was met at 97.0% (95% CI, 91.6-99.4; onesided P<0.0001). CR rate was 94.1% (95% CI, 87.5–97.8; onesided P<0.0001). With median follow-up of 16.6 and 17.5 months, respectively, median DOR and PFS were not reached; 12-month DOR and PFS were 81.9% and 80.7%, respectively. Efficacy in patients with 2L+ FL was similar. In the safety set (n=130), most common grade ≥3 treatment-emergent adverse events (TEAE) were cytopenias. One TEAE death due to grade 5 macrophage activation syndrome occurred. Cytokine release syndrome (CRS) occurred in 58% of patients (grade 3, 1%; no grade 4-5) and neurological events (NE) in 15% (grade 3, 2%; no grade 4-5). Prolonged cytopenia (grade ≥3 laboratory values at Day 29) occurred in 22% of patients and grade ≥3 infection in 5%. Conclusions: In patients with R/R FL, liso-cel demonstrated high response rates that were durable and a favorable safety profile, with low rates of grade ≥ 3 TEAEs of CRS/NEs, prolonged cytopenia, and infection. Keywords: IBCL, indolent NHL, relapsed or refractory, follicular lymphoma, liso-cel, third line or later, Phase II IBCL-099 Intensive Chemotherapy and Autologous Stem Cell (ASCT) Consolidation for Bing Neel Syndrome Jahanzaib Khwaja MBBS FRCPath1, Nicole Japzon BSc1, Ali Rismani MD1, Aisling Carr PhD2, Michael Lunn PhD2, Charalampia Kyriakou PhD1, Shirley D’Sa MD1 1University College London Hospital, London, United Kingdom. 2National Hospital for Neurology and Neurosurgery, London, United Kingdom Context: Bing-Neel syndrome (BNS) is a complication of lymphoplasmacytic lymphoma (LPL) comprising LPL infiltration in the central nervous system (CNS) with no standard of care; chemoimmunotherapy (CIT) and BTK inhibitors are effective. Use of intensive CNS-penetrating CIT for aggressive lymphomas is well-described, but BNS data is limited. Objective: To review the outcomes in our BNS cohort who have received intensive CIT and ASCT consolidation. Methods: BNS patient data referred between 2013-2021 to our Neurohaematology Center were retrospectively reviewed. Results: Of 43 symptomatic patients, median age at BNS diagnosis was 66 years (range: 43–85). All had leptomeningeal disease. Seven patients with progressive clinical features had ASCT consolidation (median age 59 years [range: 43–68]); 3 patients had additional parenchymal disease (2 also had peripheral nerve involvement, including one 1 patient with suspicion of highgrade transformation [HGT] on CSF). Most patients (4/7) were treatment-naïve; 3 patients had prior therapy. All had 2–4 cycles of intensive CIT (6, methotrexate-cytarabine-rituximab + thiotepa; 1, idarubicin-dexamethasone-cytarabine-methotrexate/etoposidemethylprednisolone-cytarabine-cisplatin) due to clinical severity. All patients showed clinical and imaging response. In 6, consolidation ASCT was delivered in first response (median of 11 months; range: 4–22) from BNS diagnosis; The other patient achieved complete response after intensive CIT, however, relapsed after 2 years and commenced ibrutinib with CNS progression, and then proceeded with ifosfamide-based therapy and ASCT. In the ASCT group, 6/7 had carmustine-thiotepa and 1 cyclophosphamide-total body irradiation (TBI) conditioning. Engraftment occurred at a median of 12 days (range: 9–13) for neutrophils,11 days (range: 10–14), for platelets); hospitalization, 21 days (range: 19–41); critical care admission and 100-day nonrelapse mortality, 0%. Median follow-up was 11 months (range: 1–96) from ASCT; 2/7 died with relapsed lymphoma >18 months from ASCT (1/7 HGT); 5/7 patients were alive; 1/7 experienced systemic relapse (postcyclophosphamide-TBIASCT) and commenced ibrutinib; 1/7 experienced CNS progression and commenced zanubrutinib. Conclusion: In our selective cohort of relatively young BNS patients with adverse clinical features (extensive CNS burden; high-grade suspicion; BNS post-BTKi/CIT failure) who proceeded with intensive chemotherapy and ASCT consolidation, treatment-related morbidity and nonrelapse mortality were low and clinical response was notable. Keywords: Bing Neel syndrome, Waldenstrom, CNS lymphoma IBCL-108 Eyelid Follicular Lymphoma Treated With Rituximab‑Bendamustine: Case Presentation Kaltrina Hoda MD1, Afërdita Ukimeraj MD1, Shemsedin Sadiku MD, PhD1,2, Endrit Ukimeraj Medical candidate1, Iliriana Alloqi Tahirbegolli MD, PhD1,3 1Hematology Clinic, University Clinical Center of Kosova, Prishtina, Kosovo. 2Faculty of Medicine, University of Prishtina “Hasan Prishtina”, Prishtina, Kosovo. 3Heimerer College, Prishtina, Kosovo Context: Ocular adnexal lymphomas (ie, lymphomas of the orbit, eyelids, conjunctiva, lacrimal gland, and lacrimal sac) constitute 2% of all extranodal lymphomas and are the most common malignant tumors of the orbit. Eyelid follicular lymphoma (FL) is a rare malignancy that presents with unique diagnostic and treatment challenges. Objective: Sharing an experience of successful
RkJQdWJsaXNoZXIy MTk3NTQxMg==